Skip to main content
. 2018 Jun 12;29(8):1822–1827. doi: 10.1093/annonc/mdy203

Figure 1.

Figure 1.

(A) OS from progression of the 1423 patients who failed to achieve PFS24 versus the expected survival from age-, sex-, and country-matched general population data. (B) OS from PFS24 of the 3678 SEAL patients who were progression free at 24 months after initiating treatment versus expected survival from age-, sex-, and country-matched general population data.